Home›Drug Classes›Kinase Inhibitors

Kinase Inhibitors

Kinase inhibitors are targeted cancer therapies that block specific enzymes driving tumor growth. They are heavily metabolized by CYP3A4 and interact with many common medications including antifungals, antibiotics, and anticonvulsants.

44 drugs in this class6 notable interactions shown

Kinase Inhibitors Drugs (44)

AbemaciclibAcalabrutinibCalquenceAfatinibGilotrifAvapritinibAyvakitAxitinibBrigatinibAlunbrigCeritinibCrizotinibErdafitinibBalversaErlotinibEverolimusEverolimusEverolimus TabletsEverolimusGefitinibIressaGorafenibIbrutinibIdelalisibZydeligLarotrectinibVitrakviLazertinibLazcluzeLenvatinibLenvimaLorlatinibLorbrenaNilotinibOsimertinibTagrissoPacritinibVonjoPalbociclibIbrancePazopanibPemigatinibPemazyrePirtobrutinibJaypircaPralsetinibGavretoRapamycinRemibrutinibRhapsidoRepotrectinibAugtyroRilzabrutinibWayrilzRipretinibQinlockRuxolitinibRydaptRydaptSelpercatinibRetevmoSelumetinibKoselugoTovorafenibOjemdaTucatinibTukysaVandetanibVemurafenibVimseltinibRomvimzaZanubrutinibBrukinsaZongertinibHernexeos

Notable Kinase Inhibitors Interactions

Abemaciclib + Ketoconazole⛔Contraindicated

Ketoconazole is predicted to increase abemaciclib AUC up to 16-fold, leading to increased toxicity. Concomitant use should be avoided.

Abemaciclib + Lopinavir And Ritonavir⛔Contraindicated

Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer agents ↓lopinavir/ritonavir # Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to KALETRA or to the class of protease inhibitors [see Contraindications ( 4 )] .

Abemaciclib + Ritonavir⛔Contraindicated

Anticancer Agents: abemaciclib, apalutamide, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer agents ↓ ritonavir # Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to NORVIR or to the class of protease inhibitors [see Contraindications ( 4 ) ] .

Acalabrutinib + Itraconazole⚠️Major

Strong CYP3A inhibitor increases acalabrutinib plasma concentrations, potentially resulting in increased toxicity. Avoid co-administration or interrupt acalabrutinib if short-term use needed.

Acalabrutinib + Rifampin⚠️Major

Strong CYP3A inducer decreases acalabrutinib plasma concentrations, reducing CALQUENCE activity. Avoid co-administration or increase acalabrutinib dose to 200 mg every 12 hours if unavoidable.

Acalabrutinib + Antacids Containing Calcium🟡Moderate

Antacid may decrease acalabrutinib plasma concentrations. Separate dosing by at least 2 hours.

Check Your Kinase Inhibitors Interactions

Enter your specific medications to see all interactions — including combinations with Kinase Inhibitors drugs.

Check Interactions →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.